This product comprises a CRISPR/Cas9-edited polyclonal knockout cell population of HeLa cells featuring targeted disruption of the DOCK4 gene. The polyclonal format consists of a heterogeneous pool of cells carrying diverse loss-of-function mutations introduced by non-homologous end joining repair following Cas9-mediated double-strand breaks. This approach avoids clonal selection artifacts and maintains genetic diversity, providing a robust and reproducible knockout model. The DOCK4-disrupted HeLa polyclonal cells serve as a powerful tool for dissecting DOCK4-dependent cellular functions, particularly in the context of cancer cell biology.
The host HeLa cell line is a human cervical adenocarcinoma line that has been immortalized through integration of human papillomavirus 18 (HPV18) DNA, leading to inactivation of the p53 and retinoblastoma (Rb) tumor suppressors. Established in 1951, HeLa cells exhibit genomic instability, aneuploidy, and aggressive proliferative capacity, making them a widely used model for cervical cancer and general cancer research. Their well-characterized signaling landscape and ease of genetic manipulation render them an ideal background for knockout studies aimed at elucidating gene function in tumorigenic and metastatic processes.
DOCK4 encodes a dedicator of cytokinesis 4 protein that functions as a guanine nucleotide exchange factor (GEF) specific for the small GTPase Rac1. By catalyzing the exchange of GDP for GTP, DOCK4 activates Rac1, which in turn stimulates downstream effectors including PAK1/2/3, JNK, and the Arp2/3 complex to promote actin polymerization, lamellipodia formation, and cell migration. DOCK4 activity is regulated by upstream signals such as Wnt5a, epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and integrin engagement, often in concert with PI3K/Akt pathway activation. DOCK4 forms functional complexes with ELMO1 and ELMO2, and interacts with ??-catenin, linking Rac1 signaling to the Wnt/??-catenin pathway. Known downstream transcriptional targets include c-Jun and cyclin D1, which are induced following Rac1-mediated JNK activation.
In the HeLa cervical cancer context, DOCK4 knockout provides a valuable model for investigating the molecular mechanisms underlying cancer cell invasion and metastasis. HeLa cells exhibit robust migratory and invasive properties partly driven by Rac1-mediated actin cytoskeletal remodeling, and DOCK4 disruption is expected to attenuate these phenotypes. Therefore, this polyclonal knockout population allows researchers to dissect the specific contribution of DOCK4 to metastatic potential, independent of clonal variation. Moreover, the interplay between DOCK4 and components of the Wnt/??-catenin pathway in HeLa cells offers a platform to study cross-talk between cell adhesion, migration, and proliferation signals in cervical adenocarcinoma.
This DOCK4 knockout HeLa polyclonal cell product is suited for a broad range of experimental applications, including Rac1 activation assays (e.g., G-LISA or PAK-PBD pull-down), Boyden chamber migration assays, Matrigel invasion assays, and wound healing assays to quantify cell motility. Immunofluorescence staining for F-actin and lamellipodia, western blotting for phosphorylated PAK1, and co-immunoprecipitation of DOCK4-ELMO complexes can be employed to characterize downstream signaling. Transcriptomic analyses via RNA-seq or RT-qPCR for targets like c-Jun and cyclin D1, as well as high-throughput screening for Rac1 pathway inhibitors such as NSC23766, are readily performed. In vivo xenograft metastasis models can further validate functional outcomes. For further information, please contact Ascent Research.
